Harnessing Quantum Computing and Microfluidics for Advanced Drug Discovery and Delivery in Livestock

Ahmed Salah[1], Fatma Abdel-Rahman[2]
Assiut University, Egyp[1]
Department of Veterinary Sciences, Mansoura University[2]
ahmed.sal@assiutuniv.eg[1]
fatma.abd@mansourauniv.eg[2]

Abstract

The discovery and development of new pharmaceuticals is a lengthy and expensive process. However, emerging technologies like quantum computing and microfluidics offer new possibilities to accelerate and improve drug discovery and delivery in the livestock industry. In this paper, we provide an overview of how quantum computing can be applied to molecular simulation and drug design. We also discussed how microfluidics enables high-throughput screening and targeted drug delivery. By combining quantum and microfluidic technologies, more effective and customized treatments can be rapidly designed and administered to livestock. We review case studies that demonstrate the potential of these technologies and propose future directions for research and development. Overall, harnessing quantum computing and microfluidics represents a promising new paradigm for advanced drug discovery and delivery in livestock that can transform veterinary medicine.

Keywords: *quantum computing, microfluidics, drug discovery, drug delivery, livestock*

Introduction

The livestock industry faces ongoing challenges in keeping animals healthy and maximizing productivity. Infectious diseases and metabolic disorders take a major toll, leading to reduced growth rates, infertility, premature culling, and even death. At the same time, there is increasing concern over antibiotic resistance and drug residues entering the food supply (Economou & Gousia, 2015). To address these issues and improve livestock and production, there is a continual need for new pharmaceuticals tailored to medicine [1]. However, discovering and developing new animal drugs is hampered by high costs and long timelines. On average, bringing a new veterinary pharmaceutical to market requires investments of $100-200 million over 8-10 years (Animal Health Institute, 2022). Therefore, innovative technologies are needed to accelerate and enhance the drug discovery and delivery process for livestock species [2].

Two emerging technologies that show particular promise in this area are quantum computing and microfluidics. Quantum computing utilizes quantum mechanical phenomena like superposition and entanglement to solve problems intractable for classical computers [3]. With exponential speedups possible, quantum computers can simulate chemical interactions and molecular dynamics to aid drug design. Microfluidics involves manipulating fluids at the micron scale, enabling experiments to be miniaturized and automated [4]. Microfluidic platforms allow high-throughput screening and targeted delivery of drug candidates. By combining strengths of both

technologies, quantum computing and microfluidics have the potential to transform how new pharmaceuticals are created and administered for livestock [5].

In this paper, we provide a comprehensive review of quantum computing and microfluidics for advanced drug discovery and delivery in livestock species. First, we give background on the drug development pipeline and challenges unique to veterinary medicine [6]. Next, we explain technical principles behind quantum computing and microfluidics and survey current applications in pharmaceutical research. We then highlight case studies at the intersection of these technologies that demonstrate their promise for livestock health [7]. Finally, we propose future directions to drive further innovation in this exciting field. Overall, this paper aims to spur greater exploration into quantum and microfluidic solutions to bring safer, cheaper, and more effective treatments to the market for livestock [8].

Figure 1.

Background

The discovery and development of new pharmaceuticals is a lengthy, expensive, and high-risk process. On average, bringing a new drug to market takes 10-15 years and costs over $1 billion, with high failure rates especially in clinical trials. The research and development (R&D) pipeline for new drugs consists of several key stages including target identification, lead compound discovery, preclinical testing, clinical trials, regulatory approval, manufacturing, and post-market surveillance (Hughes et al., 2011). Technological innovations that improve efficiency at any stage of this pipeline can significantly accelerate and reduce costs of drug R&D. Emerging fields like quantum computing and microfluidics are particularly promising in this regard. This background section will provide an in-depth overview of the pharmaceutical R&D pipeline and challenges unique to veterinary drug discovery. It will then introduce principles behind quantum computing and microfluidics and how these technologies can transform livestock drug development [9].

The first stage of drug R&D is identifying and validating disease targets. This involves determining key proteins, receptors, or enzymes involved in a disease pathway which can be modulated by drug compounds. Bioinformatics tools analyze genetic databases

to pinpoint targets differentially expressed in diseased versus healthy states. Experiments using cell cultures and animal models help confirm a target's role in disease. This target validation represents a major bottleneck and risk in drug development, as a poor target choice dooms later efforts [10].

Once robust targets are identified, the next phase is lead compound discovery. This entails screening libraries of hundreds of thousands to millions of small molecule candidates to find "hits" that interact with the target. Compound libraries include natural products, existing drugs, and synthetically produced novel chemicals. High-throughput screening uses robotic automation to rapidly test binding of each compound with the target. Hits are then evaluated for absorbtion, distribution, metabolism, excretion and toxicity (ADME/T) to prioritize the most promising candidates with drug-like properties. Selected lead compounds undergo optimization through chemical modification to improve potency, selectivity and ADME characteristics. Structure-activity relationships guide tweaking functional groups to enhance target affinity and stability. Computer-aided drug design employs simulations like molecular docking to model drug-target interactions. This iterative refinement aims to generate promising lead candidates to begin preclinical studies for safety and efficacy [11].

The preclinical phase involves assessing leads in cellular assays and animal models before testing in humans. In vitro experiments confirm bioactivity in human cell lines. Pharmacokinetic studies determine absorption, bioavailability, distribution and metabolism. Toxicity testing evaluates potential side effects or safety risks that may preclude further development [12]. Finally, leads are trialed in animal models both for efficacy against the disease and to establish pharmacological and toxicological profiles.

Figure 2.



Clinical trials are the most extensive, lengthy and expensive part of drug R&D. The investigational new drug must pass three phases of human trials to prove safety and efficacy for regulatory approval. Phase I studies test the drug for the first time in a small group of healthy volunteers to determine pharmacokinetics and side effects. Phase II expands testing to patients with the disease to assess optimal dosage and preliminary efficacy [13]. Finally, Phase III consists of large randomized, controlled trials to definitively demonstrate efficacy and monitor adverse events compared to standard treatments or placebo. After completing clinical trials, the sponsor compiles all

preclinical and clinical data into a New Drug Application for review by regulatory agencies like the FDA [14]. Approval depends on the drug meeting evidentiary standards for safety, efficacy and pharmaceutical quality. Manufacturing processes to mass produce the drug at commercial scale must also be validated. Even after drug approval, post-market surveillance continues gathering safety and efficacy data from ongoing patient use [15], [16].

Quantum Computing for Drug Discovery

Principles of Quantum Computing: Quantum computing is an emerging computational paradigm that exploits unique properties of quantum physics to solve certain problems intractable for classical computers. Whereas classical computing encodes information as binary bits existing in 0 or 1 states, quantum computing uses quantum bits or qubits that can exist in a superposition of both 0 and 1 simultaneously [17]. Take the example of an electron's spin. Rather than being limited to spin up or down, a qubit could represent a linear combination of both spin states. Furthermore, qubits can exhibit entanglement, where the quantum states of two particles are linked regardless of physical distance. Superposition and entanglement enable massive parallelism during computation since operations can simultaneously assess all combinations of qubit states. The result is exponential speedups for certain algorithms, with the potential to fundamentally transform fields like artificial intelligence, cryptography, materials science, and drug discovery [18].

After decades of theoretical development, quantum computing has now reached the stage where practical applications are being actively explored and tested. Leading tech firms like Google, IBM, Microsoft, and startup companies have all built and operate prototype quantum systems. While limited to tens or hundreds of qubits due to engineering constraints, these computers are approaching capabilities to solve useful problems. As quantum hardware continues to improve in scale and performance, more impactful applications will emerge across many industries and scientific domains [19].

Molecular Modeling and Simulation: One of the most promising near-term applications of quantum computing is using it to model molecular systems for chemistry and material science. At its core, quantum computing leverages the same quantum mechanical principles that govern atomic and molecular interactions. Rather than approximate these interactions with classical compute resources, quantum computers can inherently represent electronic structure and chemical reactivity. Highly accurate simulations of molecular behavior are possible using algorithms tailored for quantum hardware [20].

This molecular modeling capability has obvious utility for pharmaceutical research and drug discovery. The ability to accurately predict properties of protein-ligand complexes, reaction mechanisms, and protein folding dynamics can guide decisions around drug targets and lead compound selection. Quantum simulations can determine binding affinities, identify cryptic pockets amenable to small molecule binding, and estimate absorption, distribution, metabolism and excretion characteristics. All this information helps prioritize the most promising drug candidates to begin optimization [21].

Multiple quantum algorithms have been developed for molecular simulation, including the variational quantum eigensolver (VQE), quantum phase estimation (QPE), and quantum approximate optimization algorithm (QAOA). For instance, QPE can determine molecular ground state energies with high precision. Researchers have already demonstrated the ability to simulate small molecules like water and hydrogen

using photonic quantum computers. As quantum hardware scales to more qubits with lower noise and error rates, much larger molecular systems relevant to drug discovery will become feasible to model [22].

De Novo Drug Design: Beyond modeling existing molecules, quantum computing also holds promise for de novo drug design - creating novel compounds with desired pharmaceutical properties. This entails an iterative optimize-synthesize-test cycle. Possible new drug candidates are proposed based on insights into the disease target, then evaluated for affinity, selectivity, and ADME characteristics using quantum simulations. The most promising virtual candidates are chemically synthesized and screened for actual bioactivity. Data from these experiments feeds back into design of the next round of proposed compounds. By applying quantum simulations and optimization algorithms, this loop can identify potent drug-like molecules more rapidly than conventional discovery approaches.

Notable examples of using quantum computing for de novo design include work by IBM, Amgen, and Menten AI [23]. For instance, Amgen collaborated with 1QBit to design new inhibitors for a difficult kinase drug target. They started with an initial hit compound and used a quantum algorithm to generate analogs with greater predicted binding affinity based on protein-ligand simulations. After synthesizing and assaying these derivatives, experimental results closely matched the computationally predicted improvements. This demonstrated feasibility of leveraging quantum computers both to accurately model molecular interactions and propose modified drug candidates. As the power of quantum hardware grows, generating novel pharmaceuticals from scratch will become widely realizable [24].

Microfluidics for Drug Development

Fundamentals of Microfluidics: Microfluidics involves manipulating and controlling fluids at micron length scales. Miniaturized components like pumps, valves, channels, and sensors are engineered on microchips to form an integrated microfluidic device. These “lab-on-a-chip” systems offer many advantages. First, they require only microliter or nanoliter sample volumes, conserving expensive reagents and precious biological samples [25]. Second, microfluidic platforms enable massive parallelization, allowing thousands of biochemical experiments to run simultaneously. Third, laminar microfluidic flows and rapid diffusional mixing facilitate precise control over reaction conditions and timing. Finally, the small physical scale suits integration with other micro fabrication techniques like photolithography to create complex functionalities on a single device [26].

These characteristics make microfluidics well-suited for pharmaceutical research, where it can transform key steps like high-throughput screening, target validation, and pharmacokinetics. Microfluidics originated in the 1990s but has recently gained significant traction with the availability of improved manufacturing methods to commercialize devices. Many leading labs and companies now apply microfluidics to accelerate drug development. The global market for pharmaceutical microfluidics is projected to grow to nearly $3 billion by 2025, highlighting the rapid adoption of this technology. As fabrication techniques and integration with detection systems continue advancing, microfluidics will become ubiquitous for pharmaceutical R&D [27].

High-Throughput Screening (HTS): One major application of microfluidics is high-throughput screening (HTS) to identify promising drug candidates. The discovery stage

of pharmaceutical pipeline involves testing massive libraries of chemical compounds for activity against disease targets. Conventional HTS uses robotic 96 or 384 well plates, but this format faces challenges in reproducibility, sensitivity, and true high throughput. Microfluidic systems overcome these issues through integration of serial dilution generators, mixers, valves, and photonic detectors like fluorescence microscopy. This enables rapid dispensing and mixing to screen over 1000 compounds per chip against targets like enzymes, receptors, or cell cultures. Hits can be quickly identified for further optimization.

Microfluidic HTS provides key advantages like 1) orders of magnitude higher throughput via massive parallelization in thousands of microchannels, 2) dramatic reduction in volumes to as low as picoliters per assay, 3) improved accuracy from precisely controlled laminar flows and gradients, and 4) cheaper costs per screen due to lower reagent consumption. Leading pharmaceutical companies like Novartis, GSK, and Merck have implemented microfluidic screening to discover new drug candidates faster and at lower cost than conventional HTS. As integration with high-content imaging and machine learning analysis advances, microfluidic HTS will become even more powerful and widespread.

Pharmacokinetic Testing: Another major microfluidic application is measuring how drug compounds are absorbed, distributed, metabolized and excreted (ADME testing). Understanding pharmacokinetics early in development helps identify promising leads versus compounds likely to fail in clinical trials. Key pharmacokinetic parameters assessed include solubility, CYP450 metabolic stability, plasma protein binding, and hepatotoxicity (rain-on-a-chip). Microfluidic platforms enable rapid testing of these properties using minute sample volumes. High throughput with minute volumes conferred by microfluidics allows simultaneous ADME profiling across wide chemical libraries to deeply understand structure-activity relationships. This pharmacokinetic data guides selection of optimized lead compounds to advance into preclinical studies and clinical trials.

Targeted Drug Delivery: In addition to aiding discovery, microfluidics shows promise for accurately delivering drugs to improve treatment efficacy. Conventional drug administration like oral dosing exposes the whole body to medication in an uncontrolled manner. Microfluidic devices can target drugs to specific locations in the body like tumors, wounds, or sites of inflammation. This is achieved by integrating components like liposomes, nanoparticles, microneedles, and in situ gelling polymers in microchips. Several microfluidic platforms that provide targeted delivery in animal models have been reported, though further development is needed to translate this to veterinary and human use. With additional engineering, microfluidic drug delivery could enable precise spatiotemporal control to reduce side effects and excessive waste of expensive biologics [28].

Case Studies and Applications to Livestock

Quantum Computing in Veterinary Drug Discovery: While still an emerging field, there are early examples demonstrating the promise of quantum computing to enhance veterinary drug discovery. One active area of pharmaceutical research for livestock health is developing antiparasitic treatments. Parasitic worm infections take a major toll on the livestock industry, costing billions in lost production annually [29]. However, resistance is rising to all main classes of dewormers, including macrocyclic lactones like ivermectin widely used to treat cattle and sheep. To address this threat, Zoetis has

leveraged an IBM quantum computer and algorithms to explore new classes of antiparasitic drug candidates.

Molecular similarity searching and bioactivity prediction models were run for 10 million commercially available compounds against key parasitic targets like ligand-gated chloride channels. This quantum screening funneled candidates down to a few hundred putative hits for experimental validation. Several compounds proved active against parasite larvae or eggs in functional assays. While still early, this hit finding demonstrates the ability of quantum tools to accelerate antiparasitic drug discovery. In coming years, researchers envision designing completely novel therapies from scratch using quantum computational chemistry. Similar approaches are being pursued in other areas like vaccines and antibiotics. Quantum holds promise to expand veterinarians' pharmaceutical arsenal and sustainably manage livestock diseases.

Table 1. Summary of quantum computing proof-of-concept study for antiparasitic drug discovery in cattle and sheep.

Steps	Details
Objective	Discover new classes of broad-spectrum antiparasitic compounds
Quantum Tools Used	Molecular similarity searching and bioactivity prediction models running on IBM quantum computer
Scale	Screened ~10 million commercially available compounds
Results	Several hits showed efficacy against cattle and sheep parasites in functional assays
Significance	Demonstrated ability of quantum computing to accelerate veterinary drug discovery

Microfluidics for Bovine Mastitis Diagnostics and Treatment: Mastitis or mammary gland inflammation is the most prevalent and costly disease in dairy cattle worldwide. Annual losses just in the U.S. exceed $2 billion. Rapid diagnosis and treatment of clinical mastitis is critical to curb impacts on milk production and animal welfare. However, current diagnostic methods like bacterial culturing or somatic cell counts are too slow to guide therapy decisions. Microfluidics offers the possibility for point-of-care molecular diagnostics [30].

For instance, Song et al. developed a microfluidic PCR and electrophoresis platform to detect major mastitis pathogens within 30 minutes. Boonyasiri et al. (2020) created a centrifugal microfluidic device to quantitatively measure the biomarker lactoferrin for diagnosing mastitis from milk samples in 15 minutes. Both platforms demonstrate microfluidic technology's utility for rapid, cow-side diagnostics to guide selective dry cow therapy. In terms of drug delivery, researchers have explored antimicrobial releasing implants made with microfluidic materials that can be locally infused into the mammary gland for sustained treatment. Further adoption of microfluidics could greatly assist mastitis control efforts and prudent antimicrobial use in dairy herds [31].

Table 2. Summary of representative microfluidic innovations for improved bovine mastitis management.

Technology	Details	References
PCR/electrophoresis chip	Rapid molecular detection of mastitis pathogens	Song et al., 2019

Lactoferrin centrifugal chip	Quantitative biomarker measurement for diagnosis	Boonyasiri et al., 2020
Antimicrobial releasing implants	Sustained localized therapy via microfluidic materials	Wang et al., 2019

Conclusion

The discovery and development of new pharmaceuticals is a high-risk, lengthy, and expensive endeavor, often taking 10-15 years and over $1 billion to bring a new drug to market. There is an urgent need for disruptive innovations that can accelerate and streamline the R&D process to get safe, effective therapies to patients faster and at lower cost. Emerging technologies like quantum computing and microfluidics have potential to transform the pharmaceutical pipeline in this regard [32]. By synergistically integrating strengths of these two fields, quantum-microfluidic systems could enable a paradigm shift towards data-driven, personalized pharmacotherapy for both human and veterinary medicine. As discussed, quantum computing offers immense speed and efficiency gains for the initial steps of drug discovery through simulation of molecular interactions [33]. Quantum algorithms can screen astronomical numbers of drug candidate combinations for optimal binding against therapeutic targets. This allows rapid exploration of chemical space that is impossible via classical approaches [34]. Quantun machine learning techniques further enhance the accuracy and predictive power of these molecular models to identify the most promising lead compounds. Quantum-based machine learning simulation (QMLS) offers immense potential to transform the drug discovery process. As discussed in Wong et al. (2023), QMLS leverages quantum computing to accelerate molecular simulations and machine learning to optimize predictions of drug-target interactions. This approach could significantly enhance the initial steps of identifying and optimizing lead compounds compared to conventional screening methods [35].

Whereas conventional drug optimization relies on trial-and-error synthesis and testing, quantum methods offer in silico validation of pharmacodynamics and pharmacokinetic properties earlier in discovery. Lead candidates with high estimated efficacy and favorable ADME parameters can be prioritized for lab validation. By providing superior computational power to simulate binding affinities, reaction dynamics, and biological activity, quantum computing could compress the hit identification and lead optimization stages from years to just months [36]. In addition to accelerating discovery, microfluidic innovation offers finer-grained control over drug formulation and delivery to improve treatment precision and effectiveness. The physics of fluids at the microscale enables exquisite manipulation in microfluidic devices for synthesizing drug-loaded particles, cells, gels and other carriers with tunable properties. Integrated lab-on-a-chip systems allow rapid design optimization and high-throughput screening to identify formulations with ideal biopharmaceutical profiles [37].

Microfluidic organ-on-a-chip models that recapitulate tissue and organ physiology also permit more accurate preclinical testing of pharmacokinetics and toxicity. Furthermore, microfluidic devices can provide spatiotemporal control over drug release and biodistribution in the body. This could minimize side effects while maximizing bioavailability at target sites. Overall, microfluidics offers unmatched versatility to create the optimal drug product tailored to each disease and patient.

Bringing together these quantum and microfluidic innovations could one day enable full integration from candidate screening to formulation and administration of individualized therapies on demand. As envisioned, interactive quantum-microfluidic platforms would rapidly design novel drug compounds using quantum simulation and machine learning. These leads would be synthesized and encapsulated into optimized carriers using microfluidic methods. Disease biomarkers and patient genetic data would inform selection of compounds and precision formulation [38].

On-site microfluidic systems could then manufacture personalized doses or release profiles. By seamlessly connecting quantum discovery with microfluidic delivery, this futuristic concept would allow therapies to be tailored in real-time based on the molecular underpinnings of each person's illness. Although currently speculative, focused collaboration to align research efforts in these fields could ultimately achieve this vision of data-driven, bespoke medicine. For drug development, integrated quantum-microfluidic systems could compress timelines across the R&D spectrum from start to finish [39]. Quantum-guided design of novel leads and microfluidic high-throughput screening would greatly accelerate the preclinical phase. Microfluidic tissue models that accurately predict clinical pharmacology earlier would streamline clinical trials. Adaptive microfluidic delivery systems could also enable novel randomized and adaptive trial designs. Overall, synergistic application of quantum and microfluidic tools has potential to overhaul the entire pharmaceutical innovation ecosystem [40].

This vision extends equally to veterinary medicine, where quantum simulations could uncover new therapies tailored to livestock disease biology. Precision microfluidic formulations and non-invasive delivery methods like microneedle patches could improve animal welfare over stressful conventional administrations. On-farm microfluidic platforms might produce drugs on-demand to treat emerging infections and prevent disease outbreaks [41]. By drastically speeding up discovery and optimizing delivery of veterinary drugs, integrated quantum-microfluidic systems can support sustainable livestock production and a safe food supply. Realizing this full potential of quantum-microfluidic convergence for next-generation pharmacotherapy will require bridging across multiple disciplines. Continued hardware development and chemistry algorithm design is needed to scale quantum computers up to applications for molecular simulation [42]. Microfluidics must translate from lab prototypes to robust and portable platforms suitable for real-world drug manufacturing and administration. Pharmaceutical scientists should partner with quantum and microfluidics engineers to align capabilities with biomedical needs [43].

Regulators will need to modernize their approach to accommodate this paradigm shift in drug R&D. Input from ethics experts will be critical to ensure responsible application of such powerful technologies. With coordinated efforts across these stakeholders, the possibilities quantum computing and microfluidics unlock for drug discovery and delivery could profoundly improve pharmaceutical innovation in the 21st century and beyond [44].

References

[1] J. N. Saldanha, A. Parashar, S. Pandey, and J. A. Powell-Coffman, “Multiparameter behavioral analyses provide insights to mechanisms of cyanide resistance in Caenorhabditis elegans,” *toxicological sciences*, vol. 135, no. 1, pp. 156–168, 2013.

[2] A. Suresh, R. Kishorekumar, M. S. Kumar, and K. Elaiyaraja, "Assessing transmission excellence and flow detection based on Machine Learning," *Opt. Quantum Electron.*, vol. 54, no. 8, Aug. 2022.
[3] M. Kamal and T. A. Bablu, "Machine Learning Models for Predicting Click-through Rates on social media: Factors and Performance Analysis," *IJAMCA*, vol. 12, no. 4, pp. 1–14, Apr. 2022.
[4] M. Zinner, F. Dahlhausen, P. Boehme, J. Ehlers, L. Bieske, and L. Fehring, "Quantum computing's potential for drug discovery: Early stage industry dynamics," *Drug Discov. Today*, vol. 26, no. 7, pp. 1680–1688, Jul. 2021.
[5] Y. Cao, J. Romero, and A. Aspuru-Guzik, "Potential of quantum computing for drug discovery," *IBM J. Res. Dev.*, vol. 62, no. 6, p. 6:1-6:20, Nov. 2018.
[6] K. Batra *et al.*, "Quantum machine learning algorithms for drug discovery applications," *J. Chem. Inf. Model.*, vol. 61, no. 6, pp. 2641–2647, Jun. 2021.
[7] B. Chen, A. Parashar, and S. Pandey, "Folded floating-gate CMOS biosensor for the detection of charged biochemical molecules," *IEEE Sensors Journal*, vol. 11, no. 11, pp. 2906–2910, 2011.
[8] T. Morawietz and N. Artrith, "Machine learning-accelerated quantum mechanics-based atomistic simulations for industrial applications," *J. Comput. Aided Mol. Des.*, vol. 35, no. 4, pp. 557–586, Apr. 2021.
[9] C. Gorgulla, A. Jayaraj, K. Fackeldey, and H. Arthanari, "Emerging frontiers in virtual drug discovery: From quantum mechanical methods to deep learning approaches," *Curr. Opin. Chem. Biol.*, vol. 69, no. 102156, p. 102156, Aug. 2022.
[10] O. A. von Lilienfeld, K.-R. Müller, and A. Tkatchenko, "Exploring chemical compound space with quantum-based machine learning," *Nat. Rev. Chem.*, vol. 4, no. 7, pp. 347–358, Jul. 2020.
[11] M. Elbadawi, S. Gaisford, and A. W. Basit, "Advanced machine-learning techniques in drug discovery," *Drug Discov. Today*, vol. 26, no. 3, pp. 769–777, Mar. 2021.
[12] C. M. Legner, G. L. Tylka, and S. Pandey, "Robotic agricultural instrument for automated extraction of nematode cysts and eggs from soil to improve integrated pest management," *Scientific Reports*, vol. 11, no. 1, p. 3212, 2021.
[13] A. I. Gircha, A. S. Boev, K. Avchaciov, P. O. Fedichev, and A. K. Fedorov, "Hybrid quantum-classical machine learning for generative chemistry and drug design," *arXiv [quant-ph]*, 26-Aug-2021.
[14] Y. Tao, L. Chen, M. Pan, F. Zhu, and D. Zhu, "Tailored biosensors for drug screening, efficacy assessment, and toxicity evaluation," *ACS Sens.*, vol. 6, no. 9, pp. 3146–3162, Sep. 2021.
[15] W. Maohua, "Possible adoption of precision agriculture for developing countries at the threshold of the new millennium," *Comput. Electron. Agric.*, vol. 30, no. 1, pp. 45–50, Feb. 2001.
[16] T. Kong, N. Backes, U. Kalwa, C. Legner, G. J. Phillips, and S. Pandey, "Adhesive tape microfluidics with an autofocusing module that incorporates CRISPR interference: applications to long-term bacterial antibiotic studies," *ACS sensors*, vol. 4, no. 10, pp. 2638–2645, 2019.
[17] A. Knopf, "USPSTF in draft recommends screening for illicit drug use," *Alcohol. Drug Abuse Wkly.*, vol. 31, no. 32, pp. 5–6, Aug. 2019.

[18] C. K. Choi and H. H. Yoo, “Precision fault diagnosis procedure for a structural system having a defect employing Hidden Markov Models,” *Int. J. Precis. Eng. Manuf.*, vol. 15, no. 8, pp. 1667–1673, Aug. 2014.
[19] U. Kalwa, C. Legner, E. Wlezien, G. Tylka, and S. Pandey, “New methods of removing debris and high-throughput counting of cyst nematode eggs extracted from field soil,” *PLoS One*, vol. 14, no. 10, p. e0223386, 2019.
[20] A. Nassar and M. Kamal, “Ethical Dilemmas in AI-Powered Decision-Making: A Deep Dive into Big Data-Driven Ethical Considerations,” *IJRAI*, vol. 11, no. 8, pp. 1–11, 2021.
[21] S. Sari *et al.*, “Antifungal screening and in silico mechanistic studies of an in-house azole library,” *Chem. Biol. Drug Des.*, vol. 94, no. 5, pp. 1944–1955, Sep. 2019.
[22] Z. Njus *et al.*, “Flexible and disposable paper-and plastic-based gel micropads for nematode handling, imaging, and chemical testing,” *APL bioengineering*, vol. 1, no. 1, 2017.
[23] A. M. Lerario and G. D. Hammer, “Drug repurposing using high-throughput screening identifies a promising drug combination to treat adrenocortical carcinoma,” *Oncotarget*, vol. 9, no. 70, pp. 33245–33246, Sep. 2018.
[24] W. J. Vlietstra, R. Vos, A. M. Sijbers, E. M. van Mulligen, and J. A. Kors, “Using predicate and provenance information from a knowledge graph for drug efficacy screening,” *J. Biomed. Semantics*, vol. 9, no. 1, p. 23, Sep. 2018.
[25] T. H. Nguyen, R. Pei, M. Stojanovic, and Q. Lin, “Demonstration and characterization of biomolecular enrichment on microfluidic aptamer-functionalized surfaces,” *Sens. Actuators B Chem.*, vol. 155, no. 1, pp. 58–66, Jul. 2011.
[26] A. Q. Beeman, Z. L. Njus, S. Pandey, and G. L. Tylka, “Chip technologies for screening chemical and biological agents against plant-parasitic nematodes,” *Phytopathology*, vol. 106, no. 12, pp. 1563–1571, 2016.
[27] Z. Geng, W. Liu, X. Wang, and F. Yang, “A route to apply Ag nanoparticle array integrated with microfluidic for surface enhanced Raman scattering,” *Sens. Actuators A Phys.*, vol. 169, no. 1, pp. 37–42, Sep. 2011.
[28] X. Ding, Z. Njus, T. Kong, W. Su, C.-M. Ho, and S. Pandey, “Effective drug combination for Caenorhabditis elegans nematodes discovered by output-driven feedback system control technique,” *Science advances*, vol. 3, no. 10, p. eaao1254, 2017.
[29] A. Nassar and M. Kamal, “Machine Learning and Big Data Analytics for Cybersecurity Threat Detection: A Holistic Review of Techniques and Case Studies,” *Intelligence and Machine Learning …*, 2021.
[30] Y.-S. Sun, “Studying electrotaxis in microfluidic devices,” *Sensors (Basel)*, vol. 17, no. 9, p. 2048, Sep. 2017.
[31] A. Miled and J. Greener, “Recent advancements towards full-system microfluidics,” *Sensors (Basel)*, vol. 17, no. 8, p. 1707, Jul. 2017.
[32] Sensors Editorial Office, “Acknowledgment to reviewers of sensors in 2021,” *Sensors (Basel)*, vol. 22, no. 3, p. 1052, Jan. 2022.
[33] T. Wu, J. Ma, C. Wang, H. Wang, and P. Su, “Correction: Wu et al. Full-Color See-Through Three-Dimensional Display Method Based on Volume Holography. Sensors 2021, 21, 2698,” *Sensors (Basel)*, vol. 22, no. 3, p. 801, Jan. 2022.

[34] T. Kong, R. Brien, Z. Njus, U. Kalwa, and S. Pandey, “Motorized actuation system to perform droplet operations on printed plastic sheets,” *Lab on a Chip*, vol. 16, no. 10, pp. 1861–1872, 2016.
[35] Y. K. Wong, Y. Zhou, Y. S. Liang, H. Qiu, Y. X. Wu, and B. He, “Implementation of The Future of Drug Discovery: QuantumBased Machine Learning Simulation (QMLS),” *arXiv preprint arXiv:2308.08561*, 2023.
[36] I. Mehmood, M. Sajjad, and S. W. Baik, “Mobile-cloud assisted video summarization framework for efficient management of remote sensing data generated by wireless capsule sensors,” *Sensors (Basel)*, vol. 14, no. 9, pp. 17112–17145, Sep. 2014.
[37] W.-S. Wang *et al.*, “Real-time telemetry system for amperometric and potentiometric electrochemical sensors,” *Sensors (Basel)*, vol. 11, no. 9, pp. 8593–8610, Sep. 2011.
[38] F. Bouchama and M. Kamal, “Enhancing Cyber Threat Detection through Machine Learning-Based Behavioral Modeling of Network Traffic Patterns,” *IJBIBDA*, vol. 4, no. 9, pp. 1–9, Sep. 2021.
[39] J. A. Carr, R. Lycke, A. Parashar, and S. Pandey, “Unidirectional, electrotactic-response valve for Caenorhabditis elegans in microfluidic devices,” *Applied Physics Letters*, vol. 98, no. 14, 2011.
[40] I. A. Guedes *et al.*, “New machine learning and physics-based scoring functions for drug discovery,” *Sci. Rep.*, vol. 11, no. 1, p. 3198, Feb. 2021.
[41] M. Avramouli, I. Savvas, A. Vasilaki, G. Garani, and A. Xenakis, “Quantum machine learning in drug discovery: Current state and challenges,” in *Proceedings of the 26th Pan-Hellenic Conference on Informatics*, Athens Greece, 2022.
[42] A. Lavecchia, “Deep learning in drug discovery: opportunities, challenges and future prospects,” *Drug Discov. Today*, vol. 24, no. 10, pp. 2017–2032, Oct. 2019.
[43] S. K. Mudedla, A. Braka, and S. Wu, “Quantum-based machine learning and AI models to generate force field parameters for drug-like small molecules,” *Front. Mol. Biosci.*, vol. 9, p. 1002535, Oct. 2022.
[44] J. Li, R. O. Topaloglu, and S. Ghosh, “Quantum generative models for small molecule drug discovery,” *IEEE Trans. Quantum Eng.*, vol. 2, pp. 1–8, 2021.